News

December 16, 2019December 16, 2019

FDA Approves Avsola, Remicade Biosimilar, to Treat Crohn’s Disease and Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Amgen’s Avsola (infliximab-axxq) — a biosimilar to Janssen’s Remicade (infliximab) — to treat adults and children with moderate-to-severe Crohn’s disease ... Read more

December 12, 2019December 17, 2019

Injection Form of Remicade Biosimilar for IBD Similar to Approved Infusion, Phase 1 Trial Shows

News

A new formulation of CT-P13, a biosimilar of Remicade (infliximab), that is given as an under-the-skin (subcutaneous) injection, was shown to be as safe and effective in treating inflammatory bowel ... Read more

December 11, 2019December 11, 2019

Engitix, Morphic Partner to Identify New Ways of Treating Intestinal Fibrosis in IBD Patients

News

Engitix and Morphic Therapeutic announced the start of a research partnership into extracellular matrix targets for treating inflammatory bowel disease (IBD) with intestinal fibrosis, known as fibrostenotic IBD. The extracellular ... Read more

December 6, 2019December 17, 2019

Therapeutic Targeting of MT1-MMP Protein May Help Halt IBD Progression, Study Suggests

News

The membrane type 1-matrix metalloproteinase (MT1-MMP) protein may be a promising therapeutic target for inflammatory bowel disease (IBD) — possibly targeting the disease in its early stages, a study ... Read more

December 4, 2019December 4, 2019

MyGut Crohn’s and Colitis Canada App Empowers IBD Patients to Manage Health, Wellness

News

Aiming to improve the lives of the more than 250,000 Canadian residents living with inflammatory bowel disease (IBD), Crohn’s and Colitis Canada is launching a health and wellness empowerment ... Read more

December 2, 2019December 2, 2019

Abivax’s Phase 2b Trial Testing ABX464 for Ulcerative Colitis Cleared to Add French Sites

News

France’s National Agency for the Safety of Medicine and Health Products (ANSM) has cleared the inclusion of French study sites for Abivax‘s new Phase 2b clinical trial, intended to ... Read more

November 25, 2019November 25, 2019

Thetis Receives Funds From Crohn’s & Colitis Foundation to Further Develop TP-317 for IBD

News

The Crohn’s & Colitis Foundation is providing funding support to Thetis Pharmaceuticals for the continuing development of the novel oral therapy TP-317 for the treatment of inflammatory bowel disease ... Read more

November 22, 2019November 22, 2019

FDA Approves Pfizer’s Abrilada, Biosimilar to Humira, for IBD and Other Inflammatory Disorders

News

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seven inflammatory disorders, including adult Crohn’s disease ... Read more

November 18, 2019November 18, 2019

Mice Exposed to High-Sugar Diet More Susceptible to IBD, Especially Colitis, Study Shows

News

A high-sugar diet may increase susceptibility to inflammatory bowel diseases (IBD), and specifically colitis, a study in mice suggests. Titled “A high-sugar diet rapidly enhances susceptibility to colitis via ... Read more

November 15, 2019November 15, 2019

Finch and Takeda Expand Their Collaboration to Target Crohn’s Treatment Development

News

Finch Therapeutics and Takeda Pharmaceutical are joining forces to develop a treatment for Crohn’s disease — expanding their partnership in their development program for inflammatory bowel disease (IBD), which includes ... Read more